<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ryan DK</submitter><funding>British Heart Foundation</funding><pagination>3000-3013</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8327328</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>87(7)</volume><pubmed_abstract>Inhibition of interleukin 6 (IL-6) signalling has been proposed as a potential cardioprotective strategy for patients with chronic kidney disease (CKD), but the direct effects of IL-6 inhibition on renal function are not known. A Mendelian randomization (MR) study was performed to investigate the association of genetically proxied inhibition of IL-6 signalling with estimated glomerular filtration rate (eGFR), CKD and blood urea nitrogen (BUN). Inverse-variance weighted MR was used as the main analysis, with sensitivity analyses performed using simple median, weighted median and MR-Egger methods. There was no evidence for an association of genetically proxied inhibition of IL-6 signalling (scaled per standard deviation unit decrease in C-reactive protein) with log eGFR (0.001, 95% confidence interval -0.004-0.007), BUN (0.009, 95% confidence interval -0.003-0.021) and CKD (odds ratio 0.948, 95% confidence interval 0.822-1.094). These findings do not raise concerns for IL-6 signalling having large adverse effects on renal function.</pubmed_abstract><journal>British journal of clinical pharmacology</journal><pubmed_title>Inhibition of interleukin 6 signalling and renal function: A Mendelian randomization study.</pubmed_title><pmcid>PMC8327328</pmcid><funding_grant_id>RE/18/4/34215</funding_grant_id><pubmed_authors>Karhunen V</pubmed_authors><pubmed_authors>Ryan DK</pubmed_authors><pubmed_authors>Gill D</pubmed_authors><pubmed_authors>Walker DJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Inhibition of interleukin 6 signalling and renal function: A Mendelian randomization study.</name><description>Inhibition of interleukin 6 (IL-6) signalling has been proposed as a potential cardioprotective strategy for patients with chronic kidney disease (CKD), but the direct effects of IL-6 inhibition on renal function are not known. A Mendelian randomization (MR) study was performed to investigate the association of genetically proxied inhibition of IL-6 signalling with estimated glomerular filtration rate (eGFR), CKD and blood urea nitrogen (BUN). Inverse-variance weighted MR was used as the main analysis, with sensitivity analyses performed using simple median, weighted median and MR-Egger methods. There was no evidence for an association of genetically proxied inhibition of IL-6 signalling (scaled per standard deviation unit decrease in C-reactive protein) with log eGFR (0.001, 95% confidence interval -0.004-0.007), BUN (0.009, 95% confidence interval -0.003-0.021) and CKD (odds ratio 0.948, 95% confidence interval 0.822-1.094). These findings do not raise concerns for IL-6 signalling having large adverse effects on renal function.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jul</publication><modification>2024-11-13T03:19:35.331Z</modification><creation>2022-02-11T05:51:11.451Z</creation></dates><accession>S-EPMC8327328</accession><cross_references><pubmed>33393675</pubmed><doi>10.1111/bcp.14725</doi></cross_references></HashMap>